STIM Neuronetics

Neuronetics to Present at the William Blair 43rd Annual Growth Stock Conference

Neuronetics to Present at the William Blair 43rd Annual Growth Stock Conference

MALVERN, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or “Neuronetics”), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, announced that the management team will present at the William Blair 43rd Annual Growth Stock Conference on Wednesday, June 7, 2023. The Company is scheduled to present at 1:00 pm Eastern Time the same day via webcast.

A live audio webcast of the presentation will be available online at the investor relations page of the Company’s website at ir.neuronetics.com. A replay of the webcast will be archived on the website for approximately 90 days.

About Neuronetics

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience and the largest TMS company in the industry, Neuronetics is redefining patient and physician expectations by designing and developing products that improve the quality of life for people suffering from psychiatric disorders. An FDA-cleared, non-drug, noninvasive treatment for people with depression, Neuronetics’ NeuroStar® Advanced Therapy system is today’s leading TMS treatment for MDD with over 5.4 million treatments delivered. NeuroStar is widely researched and backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression outcomes registry. Our NeuroStar® Advanced Therapy system is also FDA-cleared to treat people suffering from obsessive-compulsive disorder, as well as for the treatment of comorbid anxiety symptoms (“anxious depression”) for adults with MDD suffering from anxiety symptoms. Neuronetics is committed to transforming lives by offering an exceptional treatment option that produces extraordinary results. For safety information and indications for use, visit .

Investor Contact:

Mike Vallie or Mark Klausner

ICR Westwicke

443-213-0499

Media Contact:

EvolveMKD

646-517-4220



EN
24/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Neuronetics

 PRESS RELEASE

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)...

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to six new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as a material inducement to their ...

 PRESS RELEASE

Neuronetics Reports Second Quarter 2025 Financial and Operating Result...

Neuronetics Reports Second Quarter 2025 Financial and Operating Results Delivered $38.1 million total revenue in the quarter, representing 18% adjusted pro forma revenue growth Generated record Greenbrook clinic revenue of $23.0 million in the quarter Reduced cash used in operations to $3.5 million, beating guidance of under $5 million In August 2025, received an additional $10 million in funding under the existing debt agreement with Perceptive Advisors LLC MALVERN, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a ver...

 PRESS RELEASE

Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Con...

Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference MALVERN, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that Keith Sullivan, President and Chief Executive Officer, will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled...

 PRESS RELEASE

NeuroStar Announces New Publication in JAACAP Open Highlighting Treatm...

NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents Real-world data showing NeuroStar is effective in adolescents and young adults with depression from the world’s largest TMS outcomes dataset MALVERN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the publication of significant real-world findings in the Journal of the American...

 PRESS RELEASE

Neuronetics to Report Second Quarter 2025 Financial and Operating Resu...

Neuronetics to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call MALVERN, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release second quarter 2025 financial and operating results prior to market open on Tuesday, August 5, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch